alexa Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice.


Journal of Clinical & Experimental Dermatology Research

Author(s): Scheinberg M, CastaedaHernndez G, Scheinberg M, CastaedaHernndez G

Abstract Share this page

Abstract Biosimilars that were not compared in clinical trials with the compound innovator are not true biosimilars (biocopies) and are associated with risks that the clinical rheumatologist should be aware of before generalized use. This article comments on various aspects surrounding the use of such biocopies in clinical rheumatology.
This article was published in Arthritis Res Ther and referenced in Journal of Clinical & Experimental Dermatology Research

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version